news
Single-cell sequencing reveals landscape of immune cell subtypes in lung cancer tumours
Researchers have used single-cell sequencing to map the landscape of myeloid cells in tumours from patients with lung cancer...
List view / Grid view
Immunotherapy
news
Counteracting T-cell exhaustion in CAR-T cancer therapies
Engineered T-cells that target NFAT and Nr4a proteins could help to prevent the exhaustion of T-cells during CAR-T immunotherapy...
news
Immunotherapy and DNA damage repair combo could target lung cancer
Combination therapy with a CHK1 or PARP inhibitor, with an immune checkpoint inhibitor caused the regression of small cell lung cancer in all mice treated...
news
Sartorius Stedim Biotech introduces BIOSTAT® RM TX with Flexsafe® RM TX for producing consistent quality cellular products
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry announced the launch of the BIOSTAT® RM TX single-use bioreactor, a new wave mixed system developed specifically for closed, automated expansion of consistent quality cell products such as ex vivo cellular immunotherapies...
product
Intellicyt® T Cell Activation Cell and Cytokine Profiling Kit
17 January 2019 | By IntelliCyt, a Sartorius Company
Multiplexed approach to measure T-cell activation, proliferation and quantify cytokine release in a single well
article
Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
news
New approach turns immune cells into tiny anti-tumour drug factories
In lab and mouse experiments researchers have developed a method to leverage B cells to manufacture and secrete tumour-suppressing microRNAs...
article
Self-delivering RNAi: paving the way for a new class of cancer immunotherapies
Earlier this year, the National Cancer Institute published its annual report to the nation on the status of cancer stating that there will be nearly 1.8 million new cases of cancer in 2018.1 New therapies have developed over time to improve cancer patient outcomes, including antibody immunotherapies targeting immune checkpoints,…
news
War On Cancer 2018: targeted therapies in oncology
War On Cancer 2018 discussed how cancer treatments have evolved over the last few decades, and looked at the future of cancer therapies...
news
RIP1 kinase as a therapeutic target for pancreatic cancer
RIP1 has been shown to suppress the action of macrophages against the immune system and could be a potential therapeutic target for pancreatic cancer...
news
Scientists test new anti-PD-L1 cancer vaccine against melanoma
An experimental cancer vaccine that boosts the immune system's ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumours, scientists have reported...
webinar
Integrated fragment-based approach reveals enzymatic inhibitors with potential therapeutic application
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...
news
Critical cancer immunity genes identified using genetic barcoding
Genetic barcoding using Pro-codes and CRISPR could be used to identify critical cancer immunity genes to aid future therapeutics...
news
Immunotherapy could cure advanced pancreatic cancer
Immunotherapy using 'educated' killer cells could be a potential cure for pancreatic cancer, with researchers eliminating all signs of cancer from mice...
news
Alpaca immune system reveals a potential treatment for cancer
Researchers have identified camelid nanobodies that are able to block EGF, a protein that is abundant in tumour cells...